Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Assessment following hip injection Clear all

Conditions: Hip Pain
Interventions: Assessment following hip injection; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Venous Thromboembolism
Interventions: Semuloparin sodium, Enoxaparin sodium, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Lumbar Spinal Stenosis
Interventions: NSAIDs; adjunctive analgesics; adjunctive anti-depressants, Lumbar epidural injection, Joint Mobilizations (spine, sacroiliac, hip), Individualized exercises: clinical setting, Group Exercise: community setting; Drug · Procedure · Other
Lead sponsor: Michael Schneider, DC, PhD; Other
Eligibility: 60 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Venous Thromboembolism
Interventions: Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Clinical Decision Making, Nonarthritic Hip Disease
Interventions: Interdisciplinary Evaluation for Nonarthritic Hip Disease, Posture and Movement Training, Treatment-of-choice; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prosthetic Joint Infection
Interventions: TNP-2092; Drug
Lead sponsor: TenNor Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fat Consumption, Inflammatory Markers
Interventions: Inflammatory markers test in blood prior to surgery, Inflammatory markers test in CSF (cerebrospinal fluid), MOCA test, CAM-3D; Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 60 Years and older
Enrollment: 62 participants
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pain, Hip Fractures
Interventions: Femoral Nerve Block; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 60 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: New York, New York

Conditions: Knee Osteoarthritis
Interventions: BMAC injection, PRP injection, Gel-One® hyaluronate injection; Biological · Device
Lead sponsor: OhioHealth; Other
Eligibility: 40 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hip Disease
Interventions: Bupivacaine + dexamethasone, Ultrasound; Drug · Device
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Total Hip Replacement, Arthroplasty
Interventions: Butterfly IQ, Standard of Care; Procedure · Other
Lead sponsor: Anne Arundel Health System Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Annapolis, Maryland

Conditions: Venous Thromboembolism
Interventions: Enoxaparin sodium, Semuloparin sodium, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Knee Disease, Knee Infection
Interventions: [F-18]MHF; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Fracture Healing
Interventions: Placebo, Romosozumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 95 Years
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 12
States / cities: Birmingham, Alabama • Pomona, California • Aurora, Colorado + 9 more

Conditions: Osteoarthritis
Interventions: Peri-articular injection of marcaine/epinephrine, Peri-articular injection of marcaine alone; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 19 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 5,407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more

Search by objective public record fields.

Do Hip Injections Improve Short-Term Biomechanical Outcomes In Patients With Hip Pain

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

Nonarthritic Hip Disease Evaluation And Treatment

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty

Preoperative Dietary Fat Consumption and Baseline Inflammatory Markers

Improving Pain and Function in Hip Fracture

Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee

Evaluation of Anterior Quadratus Lumborum Block for Postoperative Analgesia in Hip Arthroscopy

Pain After Preoperative UltraSound Guided Hip Injections for Total Hip Arthroplasty (PUSH)

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

F18-MHF: Implants-Associated Infection Detection

Study To Assess FRacTure Healing With SclerosTin Antibody - Hip

Study Comparing Peri-articular Injection of Bupivacaine With and Without Epinephrine

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)